Comparative Pharmacology
Head-to-head clinical analysis: FLUOROURACIL versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROURACIL versus OTREXUP PFS.
FLUOROURACIL vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is metabolized to active nucleotides (FdUMP, FUTP) which incorporate into RNA and inhibit thymidylate synthase, leading to cell cycle arrest and apoptosis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
425 mg/m² IV bolus on days 1-5 every 28 days (Mayo regimen) or 400 mg/m² IV bolus on day 1, then 2400 mg/m² continuous IV infusion over 46 hours (FOLFOX regimen). For topical use, 5% cream applied twice daily for 2-4 weeks.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Clinical Note
moderateFluorouracil + Digoxin
"Fluorouracil may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFluorouracil + Digitoxin
"Fluorouracil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFluorouracil + Deslanoside
"Fluorouracil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFluorouracil + Acetyldigitoxin
"Fluorouracil may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial α-phase 10-20 min; terminal β-phase 16-20 min (no accumulation). For continuous infusion, functional half-life ~20 min. Clinically, rapid clearance necessitates infusion schedules.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Renal: 60-80% as intact drug and metabolites (primarily urea, CO2, α-fluoro-β-alanine). Fecal: <10%. Biliary: minor.
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite